Seres Therapeutics (MCRB) Reports In-Line Q1 EPS, Revenues Miss

Seres Therapeutics (NASDAQ: MCRB) reported Q1 EPS of ($0.28), in-line with the analyst estimate of ($0.28). Revenue for the quarter came in at $8.19 million versus the consensus estimate of $8.53 million.

“We were pleased to have recently achieved the important milestone of completing enrollment of our SER-109 Phase 3 ECOSPOR III clinical study in recurrent C. difficile infection, and we look forward to topline results from this study mid-year. In preparation for successful SER-109 clinical data, we are working to prepare for a potential FDA regulatory submission and executing commercial readiness activities,” said Eric D. Shaff, President and Chief Executive Officer at Seres. “During the last several months, the COVID-19 pandemic has presented unprecedented challenges around the world. Amidst the complexity of the current environment, we are very pleased to be advancing toward our Phase 3 data on plan and on time. We continue to monitor the impact on Company operations and are carefully reviewing our development plans, including for our ongoing SER-287 and SER-401 studies. Our objective is to advance these programs toward meaningful, clinically interpretable data readouts as rapidly as possible.”

For earnings history and earnings-related data on Seres Therapeutics (MCRB) click here.

You May Also Be Interested In

• H.C. Wainwright Starts Seres Therapeutics (MCRB) at Buy
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth
• DXC Collects $213,560,494.98 in Landmark IP Theft Case From TCS